Nycomed gains FDA clearance for EchoSeed:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale Nycomed Amersham's new brachytherapy seed for treating prostate cancer. EchoSeed (iodine-125) incorporates a patented grooved design and is implanted under the guidance of ultrasound imaging, facilitating optimal placement into the prostate, says the Buckinghamshire, UK firm, which will soon be known simply as Amersham. The product was launched this week at the American Urological Association meeting in Anaheim, California.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.